- Stephen OstroffActing FDA Commissioner
Tell the FDA it is time to make #HERStory
Do you believe that women deserve equal treatment when it comes to sex?
So do we!
A biological lack of desire to have sex negatively impacts the lives and relationships of 1-in-10 American women. Its official name is hypoactive sexual desire disorder – and it is women’s MOST common sexual complaint. But unfortunately, the millions of women living with this disorder don’t have a single FDA-approved treatment option for HSDD. And that’s while men have 26 FDA-approved treatments marketed for male sexual dysfunction. You read that correctly: 26.
But here’s the good news: The Food and Drug Administration is on the verge of a HUGE decision regarding the first-ever medical treatment option for women with HSDD! On June 4th, an Advisory Committee convened by the FDA will hold an official hearing on the first drug in the pipeline for HSDD and — at the meeting’s conclusion — will announce its recommendation to the Agency for potential approval. Either way, this will be a historic moment for women’s health. If the committee recommends approval, women take a major step forward in gaining access to the medical treatment options they deserve. If the committee declines to recommend approval, the pipeline of future options for women’s sexual health will likely close for years to come, forcing women with HSDD to continue to suffer without a medical treatment option.
Now more than ever, women MUST add their voices to our call for gender equity in sexual health. We need you to join us in telling the FDA to make #HERstory by acting for women and opening the door to HSDD medical treatment options that they can discuss with their doctors.
And here’s an important note: you DON’T have to be a woman to share your thoughts with the FDA. Whether you are a woman dealing with HSDD, a health care provider, an advocate for women’s rights, or you simply believe that women deserve equality when it comes to sex, now is the time to join us!
Help us tell the FDA it is time to make #HERStory and approve the first-ever HSDD medical treatment option for women!
- Acting FDA Commissioner
Last year, the Food and Drug Administration held a landmark public meeting on female sexual dysfunction and now, in just a few short weeks, an FDA Advisory Committee will officially consider the first-ever treatment for women’s most common sexual dysfunction, known as Hypoactive Sexual Desire Disorder (HSDD). I write to thank you for the Agency’s focus on an issue that impacts the quality of life of millions of American women, their partners and their families.
As you consider next steps in the approval of potential treatment options for female sexual dysfunction and, in particular, for low desire with distress, I urge you to act for the 1-in-10 couples who are
struggling with HSDD and deserve a safe and effective medical treatment option.
Women have waited long enough. It has been 17 years since the FDA approved Viagra for men’s sexual dysfunction and, in the following years, a flood of other options. Yet today, women still have ZERO FDA-approved treatments for their most common sexual complaint.
In 2015, gender equity should be the standard when it comes to access to treatments for sexual dysfunction. And the approval of safe and effective treatments MUST be a priority for action by the FDA.
You stand ready to make #HERStory with this landmark decision and we urge you to work fairly and urgently toward a solution to an unmet medical need that your own agency has rightly recognized as a top priority of focus.
Thank you for your attention.
Even the Score started this petition with a single signature, and won with 60,937 supporters. Start a petition to change something you care about.